Iamgold At 38.2% Fibonacci Retracement Level

Iamgold has pulled back to its 38.2% Fibonacci Retracement level. Personally I’m not very good at swing trading gold and silver but I wanted to make you aware of the Fibonacci Retracement setup. I did a stock trading lesson on Fibonacci Retracements here.

Iamgold Corporation is a Toronto-based international gold producer that has an annual production of approximately 800,000 ounces of gold from operations in North America, South America, and West Africa.

Iamgold

Iamgold

A pullback is taking place, which may present an opportunity for an entry off the 38.2% retracement level. There is a very little resistance above the current price.

Continue reading “Iamgold At 38.2% Fibonacci Retracement Level”

USANA Health Sciences Positive Divergence On Large Players Volume

USANA Health Sciences’ stock has formed a positive divergence on large players volume. The price action has faded over the last couple of weeks into what could be a bullish flag channel. I bought some USANA Health Sciences in my personal trading account this morning.

The 3 month change in institutional ownership is +8.02% which suggests institutional traders are accumulating this stock.

Creative Planning increased its stake in USANA Health Sciences by a whopping 528% in Q2. Victory Capital increased its stake in USANA by 124.7% in Q1. Eqis Capital acquired a new position in USANA in the Q2 worth $210,000. Nine Chapters Capital acquired a new position in USANA in Q1 worth $207,000. KCG Holdings Inc. acquired a new position in USANA in Q1 worth $248,000. Institutional investors and hedge funds own 46.3% of the company’s stock.

On August 18, 2017, USANA announced that it would expand in four European countries beginning mid-year 2018. These four new markets constitute of Romania, Germany, Italy, and Spain.

USANA Health Sciences was recently honored by inclusion in Utah Business Magazine’s Fast 50 list. This year marks the 10th consecutive time the company has made the list of fastest growing companies in Utah. USANA finished ranked number 49 on the list.

Continue reading “USANA Health Sciences Positive Divergence On Large Players Volume”

Facebook Stock Swing Long On Rising Twiggs Money Flow

Facebook stock looks like a compelling swing long trade on a rising Twiggs Money Flow. Large players volume is also rising.

Facebook will likely spend over a billion dollars on content production. The company has recently launched ‘Watch’ a new subsection on its website for viewing videos. Facebook is moving to capitalize on shifting ad dollars as ad dollars shift away from TV. For the first time, ad spending on digital surpassed TV ad spending last year. You can see Facebook Watch in action here.

Facebook Stock

Facebook stock swing long entry on rising Twiggs Money Flow and large players volume.

The chart of Facebook shows a good setup pattern on rising Twiggs Money Flow and large players volume. Recently a Pocket Pivot signal was observed. Prices have been consolidating lately setting up a momentum squeeze play:

Momentum squeeze in Facebook stock.

Facebook stock has a resistance zone just above the current price starting at $173.52. Right above this resistance zone may be a good entry point. There is a support zone below the current price at $171.03, a stop order could be placed below this zone.

Amazon Stock Twiggs Money Flow Breaks Positive

The Twiggs Money Flow on Amazon stock has broken above the zero line and has gone positive for the first time since August 7, 2017.

Amazon just rolled out Amazon Fresh in my area of Fresno, California. I signed up for the 14-day trial for Amazon Fresh and immediately canceled it because of the poor delivery times. On Saturday, I ordered 4 peaches, and a bag of shredded mild cheddar cheese. Amazon Fresh said they could not deliver it until Tuesday, LOL. I cancelled and told them I’ll just go to the grocery store myself and pick up these items in like a hour. If Amazon Fresh is going to be successful, they have to get delivery times down to same-day and at most, one day later. If they can’t do that they might as well close down their Amazon Fresh website because only the elderly and disabled are going to be willing to wait 3 or more days for their groceries to be delivered.

I think Amazon is poorly executing on their Amazon Fresh division. Amazon Fresh wasted about an hour of my time when you include the time it took me to order and then to cancel my order as well as my Amazon Fresh trial. I won’t try Amazon Fresh again for a long time. Maybe I’ll never try it again. That’s the cold hard reality of retail: first impressions are everything. Amazon has blown it in their roll out of Amazon Fresh by promising too much and then not delivering. Still, if any company can turn this around it’s Amazon.

MKM Partners recently gave Amazon a target price of $3,330 which you can read about here.

I’ve been trading in and out of Amazon stock for about a month now and it’s been a great stock to swing trade.

Amazon Stock

Amazon stock looks strong.

That’s a good basing pattern and perhaps even an inverted Head and Shoulders pattern. The 50 day moving average (blue line) is setting up a possible breakout play. Here is a swing trading lesson on breakout chart patterns.

In addition to the Twiggs Money Flow going positive, the Effective Volume study shows large players volume is still in an uptrend.

Prices have been consolidating lately forming a momentum squeeze on the chart:

stocks-to-watch amzn chart 1100x823 - Amazon Stock Twiggs Money Flow Breaks Positive

The TSI is holding its buy signal cross from August 30, 2017.

There is very little resistance above the current price. There is a support zone below the current price at $972.24, a stop order could be placed below this zone.

PowerShares DB Crude Oil Double Short Play As Summer Ends

Large players volume is surging higher in the PowerShares DB Crude Oil Double Short ETN DTO. This is the seasonally weak time of the year for oil as the summer driving season comes to an end and demand for oil drops. Short sellers often target oil at this time of year.

PowerShares DB Crude Oil Double Short ETN

PowerShares DB Crude Oil Double Short ETN

The surge in large players volume and the positive Twiggs Money Flow suggests the seasonal short oil trade is on for 2017. Playing the seasonally weak time of year by shorting oil is a bit more risky this year due to the increased probability that hurricanes will disrupt oil production in the Gulf of Mexico.

Oconee Federal Financial Stock Heavy Institutional Buying

The stock of Oconee Federal Financial stock is seeing heavy institutional trader accumulation. The three-month change in institutional ownership is a whopping +21.6%.

Oconee Federal continues to earn Bauer Financial’s 5-Star Superior Rating. This rating means Oconee Federal is among the strongest financial institutions in the country. You can find out more about Oconee Federal Financial here.

The problem I have with this stock is that I can’t identify the catalyst that is driving it higher. I talk about the importance of identifying catalysts in this lesson.

Oconee Federal Financial Stock

Oconee Federal Financial stock

The stock is thinly traded with an average volume of about 2.8K so you have to be careful trading this stock. The Effective Volume study shows that large players are accumulating the stock which supports the increase in institutional ownership. The Twiggs Money Flow is positive which also supports the idea that this stock is being accumulated.

I see this stock as a short term swing trade with the goal of a 5% profit then get out quickly. I like the clearly defined stop loss level of $26.50 in case the trade goes against us.

Clovis Oncology Stock Rising Off Uptrend Channel Line

Clovis Oncology stock is rising off its uptrend channel line as large players volume continues to rise. The uptrend is also supported by the Twiggs Money Flow which is slowly rising. I dipped my toe in the water and purchased a little bit of Clovis Oncology stock today.

Clovis Oncology News

Since the company reported earnings on August 2, 2017, Clovis Oncology shares have lost about -8%. Clovis reported a second-quarter 2017 loss of -$1.29 per share, which was narrower than the year-ago loss of -$2.07 per share. The reported loss was greater than analysts forecast of -$1.27.

Net product revenues, entirely from Rubraca, were approximately $14.6 million in the quarter, up 108.6% sequentially. Revenues beat the consensus estimate of $12.54 million. The company said that 750 new patients were registered in the quarter.

Clovis Oncology’s Rubraca has shown an impressive growth trend in 2017. The drug received accelerated approval in Dec 2016. Rubraca is a PARP inhibitor, which is approved as a monotherapy for the treatment of advanced ovarian cancer in patients who have been treated with two or more chemotherapies. Rubraca has had an almost 100% growth in sales sequentially in the second quarter of 2017. Rubraca sales were $21.7 million in the first half of 2017. The company had 1100 new patients on therapy in the period.

Two confirmatory studies – ARIEL-3 and ARIEL-4 – are being conducted by Clovis for converting the accelerated approval to continued approval of Rubraca. The company’s shares got a boost when it announced positive top-line results from ARIEL 3 in June 2017. Progression-free survival (PFS) and safety results from the ARIEL-3 study demonstrated that Rubraca had a meaningful impact in delaying disease recurrence in advanced ovarian cancer patients. Clovis is planning to file a supplemental new drug application (sNDA) to the FDA by October this year based on ARIEL-3 data to include second-line or later maintenance indication for advanced ovarian cancer on the label of Rubraca. The company expects the label expansion to increase patient population by at least four times.

Rubraca is under review in the EU for a comparable ovarian cancer indication. An approval is expected from the EU in the first quarter of 2018.

I’m hearing rumors circulating that Clovis Oncology could be a takeover candidate by the end of the year because of Rubraca and the fact that Gilead bought KITE at the end of August.

You can find out more about Clovis Oncology here.

Clovis Oncology Stock Price

Clovis Oncology stock

Clovis Oncology stock usually swings higher at this time of year according to a seasonality study. Clovis Oncology stock is rising nicely off its uptrend line. The Effective Volume study shows large players volume rising. The Twiggs Money Flow is also rising which supports the thesis that large players are accumulating Clovis Oncology stock. I explain a lot of these chart patterns on the Frequently Asked Questions page here.

CLVS does present a good setup opportunity. Prices have been consolidating lately. There is a support zone below the current price at $72.66, a stop order could be placed below this zone.

Ishares Core Short-Term US Bond In Strong Uptrend

The Ishares Core Short-Term US Bond ETF is in a strong uptrend as large players continue to buy short term bonds.

A large amount of money is going into fixed-income exchange-traded funds in the first half of 2017, easily beating 2016’s record inflows. Traders are betting that the Federal Reserve will hike rates before the end of the year. Bond traders are front-running rate hikes in short term bonds in a bet that there will be another rate hike this year and up to three in 2018.

The Ishares Core Short-Term US Bond ETF Chart

Ishares Core Short-Term US Bond ETF

ISTB has a decent setup pattern. The rising large players volume shows big players are positioning in short term bonds. The rising Twiggs Money Flow shows traders are accumulating on pullbacks. Prices have been consolidating lately. There is a resistance zone just above the current price starting at $50.45. Right above this resistance zone may be a good entry point. There is a support zone below the current price at $50.38, a stop order could be placed below this zone.

The stock screener I used to find ISTB is the one I created for GuerillaStockTrading readers on Chartmill, under the Shared Screens tab, called GST Positive Divergence. I did a video on using Chartmill to find catalysts here.

Investors Pile Into PIMCO High Yield ETF

The PIMCO 0-5 Year High Yield Corp Bd ETF Effective Volume study shows large players are piling in to the ETF in big numbers.

You might be thinking that with the Federal Reserve raising rates, bonds and bond ETFs like HYS are in big trouble. I disagree. There will always be a need for bonds in a portfolio. Anybody who is cash flow sensitive or has a need for principal at a particular date in terms of fulfilling a certain funding or a certain drawdown, fixed income is a far more predictable and less volatile asset class compared to anything in the equity markets. It offers peace of mind for those who really want some predictability in terms of outcomes and reaching their goals.

PIMCO 0-5 Year High Yield Corp Bd ETF Chart

PIMCO High Yield ETF

HYS presents a decent setup opportunity with rising large players volume. There is a big accumulation going on in high yield bonds rights now. The Twiggs Money Flow supports the thesis that large players are accumulating HYS.

Prices have been consolidating lately. There is a resistance zone just above the current price starting at $101.31. Right above this resistance zone may be a good entry point. There is a support zone below the current price at $101.24, a stop order could be placed below this zone.

The stock screener I used to find HYS and its exploding large players volume is the screener I created on Chartmill here called GST Positive Divergence. I also did a lesson on the stock screener and finding positive divergences here.